LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 398

Search options

  1. Article ; Online: Reply to Ethan B. Ludmir, Zachary R. McCaw, and Lee-Jen Wei's Letter to the Editor re: Karim Fizazi, Charles G. Drake, Tomasz M. Beer, et al. Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.032. Interpreting the Effect of Ipilimumab following Radiotherapy for Patients with Postdocetaxel Metastatic Castration-resistant Prostate Cancer.

    McHenry, M Brent / Drake, Charles G / Fizazi, Karim

    European urology

    2020  Volume 79, Issue 1, Page(s) e12–e13

    MeSH term(s) Abiraterone Acetate ; Humans ; Ipilimumab ; Male ; Prostatic Neoplasms ; Prostatic Neoplasms, Castration-Resistant ; Survivors
    Chemical Substances Ipilimumab ; Abiraterone Acetate (EM5OCB9YJ6)
    Language English
    Publishing date 2020-10-26
    Publishing country Switzerland
    Document type Letter ; Comment
    ZDB-ID 193790-x
    ISSN 1873-7560 ; 1421-993X ; 0302-2838
    ISSN (online) 1873-7560 ; 1421-993X
    ISSN 0302-2838
    DOI 10.1016/j.eururo.2020.10.012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Reply to Giandomenico Roviello, Alberto Bottini, and Daniele Generali's Letter to the Editor re: Karim Fizazi, Kim N. Chi, Johann S. de Bono, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.02.035. Corticosteroid-associated Adverse Events in Elderly Patients.

    Fizazi, Karim / De Porre, Peter / Londhe, Anil / McGowan, Tracy / Ryan, Charles J

    European urology

    2016  Volume 70, Issue 2, Page(s) e42

    Language English
    Publishing date 2016-08
    Publishing country Switzerland
    Document type Letter
    ZDB-ID 193790-x
    ISSN 1873-7560 ; 1421-993X ; 0302-2838
    ISSN (online) 1873-7560 ; 1421-993X
    ISSN 0302-2838
    DOI 10.1016/j.eururo.2016.05.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Book ; Conference proceedings: Expanding the boundaries of clinical practice

    Fizazi, Karim

    building on experience with targeted therapies ; 12 September 2008, Stockholm, Sweden ; [presentations made at the Expanding the Boundaries of Clinical Practice: Building on Experience with Targeted Therapies Satellite Symposium]

    (Annals of oncology ; 20, Suppl. 1)

    2009  

    Event/congress Expanding the Boundaries of Clinical Practice: Building on Experience with Targeted Therapies Satellite Symposium (2008, Stockholm)
    Author's details guest ed.: K. Fizazi
    Series title Annals of oncology ; 20, Suppl. 1
    Collection
    Language English
    Size i30 S. : Ill., graph. Darst.
    Publisher Oxford Univ. Press
    Publishing place Oxford
    Publishing country Great Britain
    Document type Book ; Conference proceedings
    HBZ-ID HT015947475
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  4. Article ; Online: Préface.

    Fizazi, Karim

    Bulletin du cancer

    2020  Volume 107, Issue 5S, Page(s) S1

    Title translation Preface.
    Language French
    Publishing date 2020-07-03
    Publishing country France
    Document type Editorial
    ZDB-ID 213270-9
    ISSN 1769-6917 ; 0007-4551
    ISSN (online) 1769-6917
    ISSN 0007-4551
    DOI 10.1016/S0007-4551(20)30270-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Book: A multitargeted approach: clinical advances in the treatment of solid tumours

    Fizazi, Karim

    (Annals of oncology ; 18, Suppl. 10)

    2007  

    Author's details guest ed.: K. Fizazi
    Series title Annals of oncology ; 18, Suppl. 10
    Collection
    Language English
    Size 41 S. : graph. Darst.
    Publisher Oxford Univ. Press
    Publishing place Oxford
    Publishing country Great Britain
    Document type Book
    HBZ-ID HT015307878
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  6. Book: Carcinoma of an unknown primary site

    Fizazi, Karim

    2006  

    Author's details ed. by Karim Fizazi
    Keywords Neoplasms, Unknown Primary / diagnosis ; Neoplasms, Unknown Primary / therapy ; Carcinoma / therapy ; Carcinoma / diagnosis
    Language English
    Size XV, 240 S. : Ill., graph. Darst.
    Publisher Taylor & Francis
    Publishing place New York u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT014708962
    ISBN 978-0-8247-2799-4 ; 0-8247-2799-1
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  7. Article ; Online: Options thérapeutiques en cancérologie génito-urinaire en période épidémique du COVID-19.

    Fizazi, Karim

    Bulletin du cancer

    2020  Volume 107, Issue 4, Page(s) 395–397

    Title translation Therapeutic options for genitourinary cancers during the epidemic period of COVID-19.
    MeSH term(s) Betacoronavirus ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/epidemiology ; Epidemics ; Humans ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/epidemiology ; SARS-CoV-2 ; Urogenital Neoplasms/therapy
    Keywords covid19
    Language French
    Publishing date 2020-03-27
    Publishing country France
    Document type Practice Guideline
    ZDB-ID 213270-9
    ISSN 1769-6917 ; 0007-4551
    ISSN (online) 1769-6917
    ISSN 0007-4551
    DOI 10.1016/j.bulcan.2020.03.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Design Considerations in the PSMAfore Trial.

    Sartor, Oliver / Fizazi, Karim / Herrmann, Ken / Morris, Michael J

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine

    2024  Volume 65, Issue 2, Page(s) 226–227

    Language English
    Publishing date 2024-02-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80272-4
    ISSN 1535-5667 ; 0097-9058 ; 0161-5505 ; 0022-3123
    ISSN (online) 1535-5667
    ISSN 0097-9058 ; 0161-5505 ; 0022-3123
    DOI 10.2967/jnumed.123.267034
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Current Systemic Therapy in Men with Metastatic Castration-Sensitive Prostate Cancer.

    Grisay, Guillaume / Lavaud, Pernelle / Fizazi, Karim

    Current oncology reports

    2024  

    Abstract: Purpose of review: This review aims to explore the evolving landscape of treatments available for metastatic castration-sensitive prostate cancer (mCSPC) patients.: Recent findings: In less than a decade, evidence was chronologically provided that (1) ...

    Abstract Purpose of review: This review aims to explore the evolving landscape of treatments available for metastatic castration-sensitive prostate cancer (mCSPC) patients.
    Recent findings: In less than a decade, evidence was chronologically provided that (1) systemic treatment intensification with docetaxel improves outcomes, including survival, in men with mCSPC, (2) then that these outcomes are also improved when a second-generation androgen receptor pathway inhibitor (ARPI) is combined with androgen deprivation therapy (ADT), and (3) using a "triplet systemic therapy," which consists in the combination of ADT, an ARPI and docetaxel, further improves outcomes, including survival. Radiotherapy to the prostate combined with ADT alone is now recommended in men with low-volume mCSPC. Combining prostate radiotherapy and intensified systemic treatment including abiraterone may be synergistic as suggested in the PEACE-1 trial. Also, the role of metastases-directed local therapies (mostly stereotactic radiotherapy) is currently being assessed in phase 3 trials. Finally, the integration of biomarkers (e.g. BRCA2 gene alterations, PTEN loss, PSMA expression) for decision making is not currently established, though trials are also currently underway. Importantly, most evidence currently available was obtained in men with de novo metastases, while for those with metastatic relapse after definitive local treatment, the role of treatment intensification is less well established. Treatment intensification is nowadays the standard of care for patients with de novo mCSPC as it leads to outcomes improvement, including survival, and the standard of care is evolving almost on a yearly basis.
    Language English
    Publishing date 2024-04-09
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2057359-5
    ISSN 1534-6269 ; 1523-3790
    ISSN (online) 1534-6269
    ISSN 1523-3790
    DOI 10.1007/s11912-024-01509-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top